Clinic to Commercial Manufacturing: Higher Titers and Product Quality with TransIT® AAViator GMP

TransIT-siQUEST® Transfection Reagent – 5 X 1.5 mL

A high efficiency, low toxicity, siRNA transfection reagent for mammalian cells

$2,568.00

Unsure of what transfection reagent you need? Consult Reagent AgentTM.

Description

  • Broad Spectrum siRNA Delivery – Utilize one transfection reagent and protocol for a wide variety of cells
  • Low Cellular Toxicity – Maintain cell density and reduce experimental biases
  • Reproducible Results – Obtain consistent, targeted gene knockdowns from day to day
  • High Knockdown Efficiency – Achieve optimal gene silencing in a large percentage of cells to ensure experimental success

SKU: MIR 2115

Resources

Specifications

Storage Conditions
All Configurations: Store at 4°C

Product Guarantee
All Configurations: 1 year

Usage Statement
All Configurations: For Research Use Only.

Animal Origin Statement
All Configurations: This product is animal origin free.

Technical Product Literature

Full Protocol
TransIT-siQUEST® Full Transfection Protocol (PDF)

Quick Reference Protocol
TransIT-siQUEST® Quick Ref Proocol (PDF)

SDS
TransIT-siQUEST® SDS (PDF)

Additional Resources

Technical Report: High Efficiency siRNA Delivery In Vitro (PDF)
Publication: Delivery of small interfering RNA to mammalian cells in culture
Poster: RNAi Applications in Nucleic Acid Delivery (PDF)

Cell Types successfully transfected at Mirus using TransIT-siQUEST® Transfection Reagent (PDF)

Supporting Data

 

High Knockdown and Low Toxicity Using TransIT-siQUEST® Reagent in CHO Cells Stably Expressing Firefly Luciferase. CHO-luc cells were grown in 24 wells plates and transfected with 25 nM of either a non-targeting siRNA or a anti-firefly luciferase siRNA using the indicated reagents with the volumes noted beneath each well. Luciferase expression, normalized to non-targeting siRNA control (bar graph) and lactate dehydrogenase (LDH) levels (line graph) were measured at 24 hours post-transfection. LDH levels are reported as percent cytotoxicity compared to cells alone and were measured using a commercially available colorimetric assay; all values at or below zero are represented as zero on graph.

 

Inhibition of PPAR-alpha Expression in Primary Mouse Hepatocytes Using the TransIT-siQUEST® Reagent. Primary mouse hepatocytes were transfected with an anti-PPAR-alpha siRNA or a non-targeting control siRNA using the TransIT-siQUEST® Reagent. Twenty-four hours post-transfection, the amount of PPAR-alpha mRNA was measured relative to GAPDH mRNA levels using qRT-PCR and then scaled to the expression level of the specific target mRNA in the Opti-MEM® media only (untreated) control.

 

Delivery of Fluorescently-Labeled siRNA Using TransIT-siQUEST® Transfection Reagent. HeLa (70% confluence) cells in 12-well plates were transfected with TransIT-siQUEST® Transfection Reagent (3 μl/well) and Label IT® siRNA Tracker™ Cy-3-labeled siRNA duplexes (RED, 25 nM final concentration in the well). The cells were incubated 24 hours post-transfection then fixed and counterstained with counterstained with Alexa Fluor® 488 Phalloidin (GREEN) (Life Technologies). Confocal images were acquired on a Zeiss LSM 510 Confocal Microscope.

 

Efficient Target Gene Knockdown in Selected Cell Lines Using TransIT-siQUEST® Reagent. Reporter plasmids expressing both firefly and sea pansy luciferase were co-transfected into the indicated cell lines using TransIT® Plasmid Transfection Reagents. Targeted knockdown was achieved by transfection of an anti-firefly luciferase siRNA using the TransIT-siQUEST® Reagent. Twenty-four hours later, firefly luciferase expression was normalized to sea pansy luciferase expression and compared to the reagent alone control.

FAQs

See the TransIT-siQUEST FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our programs.

Sally Mader, PhD
ZYZ Theraputics

Packaging Update Alert

We are currently transitioning to a new packaging design to ensure consistency across our product portfolio, including tube cap color. During this transition, we will continue to use existing stocks of packaging for each product line before switching to the new design. As a result, you may receive shipments containing products in either packaging configuration. We do not anticipate any impact to the quality of these products. If you have any questions or concerns, please don’t hesitate to contact our Technical Support team at mirusbio_techsupport@milliporesigma.com